Sector Experts

Stephen Dunn

LifeTech Capital

Image: Stephen Dunn

LifeTech Capital President and Senior Managing Director Stephen Dunn was previously the managing director of Life Sciences Research at Jesup & Lamont, as well as director of research for Dawson James Securities and director of Life Sciences at Cabot Adams venture capital group. He has held management positions in business development, finance and operations, having worked in more than 25 countries in North America, Europe and the Far East with biomedical companies including Beckman Coulter, Coulter, Cordis (Johnson & Johnson) and Telectronics (St. Jude Medical), as well as several smaller companies. With more than 25 years in the global biomedical industry, Dunn has negotiated numerous intellectual property licenses, product development agreements, venture funding, mergers and acquisitions and joint ventures. Dunn is a five-star biotechnology analyst on StarMine and has appeared in both the financial and scientific media, including The Wall Street Journal, CNN, Newsweek, Forbes, Nightly Business Report, Nature Biotechnology, The Scientist, BioWorld and many other media outlets. He is a frequent speaker and panel member for many financial, medical and venture capital events.




Recent Interviews

Can Stem Cells Regenerate Your Portfolio? Stephen Dunn Says Yes (9/27/12) Once the subject of intense political debate, stem cell therapies may soon be a therapeutic mainstay of healthcare. In this exclusive interview with The Life Sciences Report, LifeTech Capital's President and Senior Managing Director of Research Stephen Dunn explores the history of stem cell therapy and discusses companies that are reviving this "old" technique for profit.

Vaccine Therapies Hold Promise for Investors: Stephen Dunn (4/12/12) Developing vaccines to treat and/or prevent disease promises life-changing benefits for patients and unique opportunities for investors. In this interview with The Life Sciences Report, LifeTech Capital Senior Managing Director and President Stephen Dunn discusses the roadblocks encountered by some developers of immune therapies and how other companies are working around those obstacles, producing investment opportunities in the process.

Infectious Disease Technologies Could Open Investment Opportunities in 2012: Stephen Dunn (2/16/12) Investors have avoided infectious disease companies like the plague, but LifeTech Capital President and Senior Managing Director of Research Stephen Dunn doesn't agree, and he has staked out some ideas in this space that could make you financially better off. In this exclusive interview with The Life Sciences Report, Dunn explains the rationale and delivers the names of bug-fighting companies that use the newest technologies to overcome old barriers to success.

Recent Quotes

"STEM remains one of the most advanced players in the stem cell space." (3/24/14) StemCells Inc. - Stephen Dunn, LifeTech Capital More >

"CIRM's $19M funding for HuCNS-SC in Alzheimer's disease validates STEM's research." (1/10/14) StemCells Inc. - Stephen Dunn, LifeTech Capital More >

"STEM's strong management team and strong science continues to be successfully validated." (1/2/14) StemCells Inc. - Stephen Dunn, LifeTech Capital More >

"For investors with a long time horizon, CUR could be very rewarding." (9/27/12) Neuralstem Inc. - The Life Sciences Report Interview with Stephen Dunn More >

"KLH is the world leader in keyhole limpet hemocyanin production." (4/12/12) Stellar Biotechnologies Inc. - The Life Sciences Report Interview with Stephen Dunn More >

"IMUC's ability to manufacture 20 doses at once should significantly improve economics." (4/12/12) ImmunoCellular Therapeutics Ltd. - The Life Sciences Report Interview with Stephen Dunn More >

"MRK's HPV vaccine has solid profit margins." (4/12/12) Merck & Co. Inc. - The Life Sciences Report Interview with Stephen Dunn More >

"KLH is an under-the-radar play and the world leader in keyhole limpet hemocyanin production." (2/16/12) Stellar Biotechnologies Inc. - The Life Sciences Report Interview with Stephen Dunn More >



Due to permission requirements, not all quotes are shown.